Pivotal Therapeutics Inc. Generates Positive Feedback at European Society of Cardiology Congress 2012

Woodbridge, Ontario (ots/PRNewswire) -

Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CNSX: PVO), a specialty
pharmaceutical company with a focus on cardiovascular disease and
overall health, is pleased to announce that the company received a
positive response to its lead product VASCAZEN(TM) at the European
Society of Cardiology (ESC) Congress 2012 in Munich, Germany last
week. The ESC Congress provided the Company a platform to inform
healthcare professionals from around the world on the benefits of
VASCAZEN(TM) and its unique approach to Omega-3 therapy.

The expanded scientific study presented at the ESC Congress that
demonstrated the superiority of VASCAZEN(TM)'s formulation was well
received by the large audience of delegates interested in Omega-3 and
cardiovascular health. The study, entitled The highly purified
EPA:DHA 6:1 product evokes potent endothelium-dependent relaxations
of porcine coronary artery rings via the redox-sensitive
PI3-kinase/Akt-dependent phosphorylation of eNOS, was authored by F.
Zgheel, M. Alhosin, C. Auger and V.B. Schini-Kerth and conducted at
the University of Strasbourg, Illkirch, France.

"Scientific findings on VASCAZEN(TM)'s cellular and membrane
effects, in addition to its superior vasodilatory profile, was
presented and appreciated by a large audience of clinicians and
scientists that attended the oral presentation given at the ESC
Congress" said Dr. George Jackowski, Chairman and Chief Scientific
Officer. "This conference was attended by over 26,000 individuals
working in the cardiovascular field from all over the world, and the
data collected on our unique formulation demonstrated to this
audience that not all Omega-3 formulations are the same and showed
VASCAZEN(TM)'s superiority over other prescription only products."

About Pivotal Therapeutics Inc.

With offices in Toronto, Canada and Boca Raton, Florida, Pivotal
Therapeutics is a publicly traded (OTCQX: PVTTF); (CNSX: PVO)
specialty pharmaceutical company with a focus on cardiovascular
disease and overall health. Pivotal Therapeutics' lead product
VASCAZEN(TM) is a prescription only Medical Food formulated to meet
the dietary Omega-3 deficient needs of patients with cardiovascular
disease through elevating Eicosapentaenoic acid (EPA) and
Docosahexaenoic acid (DHA) to levels associated with reduced risk of
cardiovascular complications.

VASCAZEN(TM) is a >90% pure, proprietary EPA:DHA fatty acid
formulation, protected by a series of both issued and pending US and
foreign patents and commercialized as a prescription only Medical
Food in the U.S. This unique formulation will provide the cornerstone
upon which a family of cutting edge combination products, with
efficacy across a broad spectrum of cardiac care, will be
commercialized.

OMAZEN(TM) is a >90% pure, proprietary EPA:DHA fatty acid
formulation commercialized for sale and distribution in Canada for
the maintenance of good health through elevating Omega-3 fatty acid
levels. The unique formulation and dosage will be available to
patients and consumers who realize the health benefits of Omega-3
supplementation with a quality product.

Disclosure Notice

The information contained in this document is as of September 4,
2012. This press release contains forward-looking statements. Such
forward-looking statements are subject to a number of risks,
assumptions and uncertainties that could cause Pivotal's actual
results to differ materially from those projected in such
forward-looking statements. These statements can be identified by the
use of words such as "will", "anticipate", "estimate", "expect",
"project", "forecast", "intend", "plan", "believe", "project",
"potential", and similar expressions with any discussion of future
operating or financial performance or events. In particular, factors
that could cause actual results to differ materially from those in
forward looking statements include the following: Pivotal's inability
to obtain additional financing on acceptable terms; growth in costs
and expenses; inability to compete with others who provide comparable
products; risk that the Company's products will not gain widespread
market acceptance; risks relating to the Company's ability to
maintain its CSNX listing. Forward-looking statements speak only as
of the date made and are not guarantees of future performance. The
Company undertakes no obligation to publicly update or revise any
forward-looking statements contained in this document as a result of
new information or future events or developments. CNSX has not
reviewed and does not accept responsibility for the adequacy or
accuracy of this information.

Company Contacts:

Rachelle MacSweeney
President and Chief Operating Officer
Phone: +1-905-856-9797
E-Mail: rmacsweeney@pivotaltherapeutics.us

Kristine DiMatteo
Communications and Public Relations Manager
Phone: +1-905-856-9797 ext. 231
E-Mail: kdimatteo@pivotaltherapeutics.us

Pivotal Therapeutics Inc.
http://www.pivotaltherapeutics.us

ots Originaltext: Pivotal Therapeutics Inc.
Im Internet recherchierbar: http://www.presseportal.de